PDE5A

Across TCGA pan-cancer cohorts, PDE5A mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated PDE5A data layer compared with 28 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher PDE5A mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated PDE5A expression acts as an unfavorable survival marker, although some lineages such as PDAC and CCRCC show a favorable association.

PDAC, LUAD, and CCRCC are the cancer types where PDE5A mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Median	II,III,IV	0.918	0.764	.002	45	view →
LUAD	DFS	Quartile	II,III,IV	0.716	1.000	.005	7	view →
CCRCC	DFS	Tertile	III,IV	0.812	0.432	.028	4	view →
LSCC	OS	Tertile	All	0.939	1.000	.036	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

PDE5A–PDAC (OS)

Open the PDAC breakdown →